

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010993 A1

(51) International Patent Classification⁷: **A61K 31/397**,
31/35, 31/22, 31/365, 31/40, 47/08

(GB). **CHO, Wing-Kee, Philip** [US/US]; 2000 Galloping
Hill Road, Kenilworth, NJ 07033-0530 (US).

(21) International Application Number:
PCT/US2003/022889

(74) Agent: **QUAGLIATO, Carol, S.**; Merck & Co., Inc., 126
East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(22) International Filing Date: 22 July 2003 (22.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/398,691 26 July 2002 (26.07.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **MERCK
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,
Hoddesdon, Hertfordshire EN11 9BU (GB). **SCHERING
CORPORATION** [US/US]; 2000 Galloping Hill Road,
Kenilworth, NJ 07033-0530 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MOORE, William,
D.** [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire
EN11 9BU (GB). **FITZPATRICK, Shaun** [GB/GB];
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU
(GB). **SEILER, Christian** [DE/GB]; Hertford Road, Hod-
desdon, Hertfordshire EN11 9BU (GB). **SAKLATVALA,
Robert** [GB/GB]; Hertford Road, Hoddesdon, Hertford-
shire EN11 9BU (GB). **PETTS, Catherine, R.** [GB/GB];
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION COMPRISING A CHOLESTEROL ABSORPTION INHIBITOR, AN HMG-COA REDUCTASE IN-
HIBITOR AND A STABILIZING AGENT

(57) Abstract: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an
HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium
stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.



WO 2004/010993 A1

COMPOSITIONS COMPRISING A CHOLESTEROL ABSORPTION INHIBITOR, AN HMG-COA REDUCTASE INHIBITOR AND A STABILIZING AGENT

BACKGROUND OF THE INVENTION

5 The instant invention involves a pharmaceutical formulation for bulk composition and oral dosage units comprised of the combination of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, particularly simvastatin, with a cholesterol absorption inhibitor, particularly ezetimibe, or pharmaceutically acceptable salts, solvates or esters of these compounds, which is useful for lipid
10 management and for preventing and treating atherosclerotic diseases and related conditions and disease events.

 It has been clear for several decades that elevated blood cholesterol is a major risk factor for coronary heart disease (CHD), and many studies have shown that the risk of CHD events can be reduced by lipid-lowering therapy. Prior to 1987, the
15 lipid-lowering armamentarium was limited essentially to a low saturated fat and cholesterol diet, the bile acid sequestrants (cholestyramine and colestipol), nicotinic acid (niacin), the fibrates and probucol. Unfortunately, all of these treatments have limited efficacy or tolerability, or both. Substantial reductions in LDL (low density lipoprotein) cholesterol accompanied by increases in HDL (high density lipoprotein)
20 cholesterol could be achieved by the combination of a lipid-lowering diet and a bile acid sequestrant, with or without the addition of nicotinic acid. However, this therapy is not easy to administer or tolerate and was therefore often unsuccessful except in specialist lipid clinics. The fibrates produce a moderate reduction in LDL cholesterol accompanied by increased HDL cholesterol and a substantial reduction in
25 triglycerides, and because they are well tolerated these drugs have been more widely used. Probucol produces only a small reduction in LDL cholesterol and also reduces HDL cholesterol, which, because of the strong inverse relationship between HDL cholesterol level and CHD risk, is generally considered undesirable. With the introduction of lovastatin, the first inhibitor of HMG-CoA reductase to become
30 available for prescription in 1987, for the first time physicians were able to obtain large reductions in plasma cholesterol with very few adverse effects.

 Recent studies have unequivocally demonstrated that lovastatin, simvastatin and pravastatin, all members of the HMG-CoA reductase inhibitor class, slow the progression of atherosclerotic lesions in the coronary and carotid arteries.
35 Simvastatin and pravastatin have also been shown to reduce the risk of coronary heart

disease events, and in the case of simvastatin a highly significant reduction in the risk of coronary death and total mortality has been shown by the Scandinavian Simvastatin Survival Study. This study also provided some evidence for a reduction in cerebrovascular events.

5 Despite the substantial reduction in the risk of coronary morbidity and mortality achieved by simvastatin, the risk is still substantial in the treated patients. For example, in the Scandinavian Simvastatin Survival Study, the 42% reduction in the risk of coronary death still left 5% of the treated patients to die of their disease over the course of this 5 year study. Further reduction of risk is clearly needed.

10 Certain hydroxy-substituted azetidinones such as ezetimibe (described in U.S. Patent No.'s 5,767,115 and Re. 37721) are now known to be useful as hypocholesterolemic agents in the treatment and prevention of atherosclerosis. Cholesteryl esters are a major component of atherosclerotic lesions and the major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters is also
15 a key step in the intestinal absorption of dietary cholesterol. Thus, inhibition of cholesteryl ester formation and reduction of serum cholesterol is likely to inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.

20 Further risk reduction can be achieved with a combination therapy comprised of an HMG-CoA reductase inhibitor such as simvastatin with a cholesterol absorption inhibitor such as ezetimibe to provide lipid management, and to treat or reduce the risk of atherosclerotic disease; the combined use of these two active agents is described in U.S. Patent No. 5,846,966. Since ezetimibe can be given orally once
25 daily, like HMG-CoA reductase inhibitors such as simvastatin, it would be beneficial to combine the two active agents into a single orally administerable pharmaceutical dosage unit such as a tablet using a formulation that is stable and minimizes the degradation of the active agents.

30 The instant invention addresses this need by providing a novel formulation for bulk pharmaceutical composition and for oral pharmaceutical dosage units comprised of simvastatin and ezetimibe that can be produced in a robust process that provides a high quality finished product with minimal unwanted degradation by-products and desirable shelf-life stability.

SUMMARY OF THE INVENTION

The instant invention provides a novel pharmaceutical formulation comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor having desirable stability but which does not require the presence of ascorbic acid, nor
5 does it require the presence of pre-gelatinized starch.

More particularly, the instant invention provides a pharmaceutical composition comprised of from 1% to 20% by weight of a cholesterol absorption inhibitor such as ezetimibe; from 1% to 80% by weight of an HMG-CoA reductase inhibitor such as simvastatin; and from 0.01% to 2% by weight of a stabilizing agent
10 such as BHA. It further comprises from 1% to 80% by weight of microcrystalline cellulose; from 0.5% to 10% by weight of hydroxypropyl methylcellulose; from 0.1% to 4% by weight of magnesium stearate; and from 25% to 70% by weight of lactose. The composition may also optionally be comprised of one or more of croscarmellose sodium, citric acid, ascorbic acid and propyl gallate. Although the composition can
15 include ascorbic acid, it is not necessary to include ascorbic acid in order to obtain desirable results. Similarly, although the composition could include pre-gelatinized starch, the composition need not include pre-gelatinized starch to obtain desirable results. The composition can be prepared in bulk form and is suitable for forming into individual oral dosage units, such as tablets, which are useful for treating vascular
20 conditions such as hyperlipidemia including hypercholesterolemia and treating and preventing atherosclerotic disease and events such as myocardial infarction.


Another aspect of the present invention is a pharmaceutical composition comprising from 1 to 20% by weight of a cholesterol absorption inhibitor such as ezetimibe; from 1 to 80% by weight of at least one HMG-CoA reductase
25 inhibitor; and from 0.005 to 10% by weight of at least one stabilizing agent. Additional aspects will be evident from the following detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The instant invention is directed to formulations of HMG-CoA
30 reductase inhibitors and cholesterol absorption inhibitors. More particularly the HMG-CoA reductase inhibitor is a statin, including, for example, simvastatin, lovastatin, atorvastatin, fluvastatin, pravastatin, cerivastatin, pitavastatin and rosuvastatin. The cholesterol absorption inhibitor may be selected from any of those disclosed in U.S. Patents Nos. RE 37,721; 5,688,990; 5,656,624; 5,624,920;
35 5,698,548; 5,627,176; 5,633,246; 5,688,785; 5,688,787; 5,744,467; 5,756,470;


5,767,115 and U.S. Patent Application No. 10/166,942 filed June 11, 2002, which are incorporated herein by reference. Methods of making such compounds are also disclosed in those patents. Specifically, the instant invention is directed to formulations of simvastatin and ezetimibe.

5 Simvastatin is marketed worldwide, and sold in the U.S. under the tradename ZOCOR®. Methods for making it are described in U.S Patent No.'s 4,444,784; 4,916,239; 4,820,850; among other patent and literature publications. Simvastatin is shown below as structural formula I:



Ezetimibe is now marketed in the U.S. under the tradename ZETIA®. The ZETIA® formulation contains ezetimibe as the only active ingredient. Methods for making ezetimibe are described in U.S. Patent No.'s 5,631,365; Re. 37721; 5,846,966; 5,767,115, 6,207,822; U.S. Application No. 10/105,710 filed March 25, 2002 and PCT No. 93/02048. Ezetimibe is shown below as structural formula II, and can be in an anhydrous or hydrated form:

15



In addition to the HMG-CoA reductase inhibitor and cholesterol absorption inhibitor active agents, particularly simvastatin and ezetimibe, the instant oral pharmaceutical composition may contain one or more of microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), magnesium stearate, lactose and povidone (PVP). The composition is also comprised of one or more stabilizing agents including antioxidant agents such as, for example, butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-methylphenol (BHT), propyl gallate, ascorbic acid, citric acid, edetate disodium and calcium metabisulphite, with BHA, propyl gallate and combinations thereof being preferred, and a combination of BHA with propyl gallate being most preferred. Optionally, one or more of croscarmellose sodium (CCNa), citric acid, lactic acid, malic acid, succinic acid, tartaric acid and ethylenediaminetetraacetic acid (EDTA) and salts thereof may also be included in the composition. In particular, although ascorbic acid could be included in the composition, the composition does not require the presence of ascorbic acid as a component to achieve good results. Similarly, the composition does not require the presence of pregelatinized starch as a component to achieve good results, although pregelatinized starch could be included in the composition if desired. When the term "ascorbic acid" is used herein, it is intended to include the free acid as well as salt forms thereof, such as sodium ascorbate.

It is known that ascorbic acid tends to discolor compositions, pharmaceutical and otherwise, when it is a component. When used in pharmaceutical tablets, this discoloring effect may necessitate the use of a coating over the tablet to mask the discoloration. Since the composition of this invention can be formulated without ascorbic acid, such tablets formed without ascorbic acid can be prepared without the extra step of adding a film coating. Of course, a film coating could be added if desired, for example for aesthetic purposes, but the need to add a coating to mask the discoloration caused by ascorbic acid is removed.

As used herein, the terms "pharmaceutical composition" and "composition" encompass both the bulk composition and individual oral dosage units (tablets, pills and the like) comprised of the two pharmaceutically active agents, e.g. simvastatin and ezetimibe, with the pharmaceutically inactive excipients described herein (the active agents and the excipients are collectively referred to herein as the "components" of the composition). The bulk composition is material that has not yet been formed into individual oral dosage units. The oral dosage unit form of the pharmaceutical composition is preferably a tablet.

Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about."

5 As intended herein, the total weight of a single oral dosage unit, e.g. the weight of one tablet, is determined by adding the weights of all the components (i.e., the two active agents and the excipients) in the dosage unit, and does not include the weight of any coatings which may optionally be externally applied to the dosage unit after it has been formed from the bulk composition. It also does not include any
10 solvents used during the granulation process which are subsequently removed during drying. The total weight of a single oral dosage unit as defined above is used as the basis for calculating the weight percentage of each of the components that comprise the dosage unit. However, dosage units comprised of the components described herein that are uncoated as well as those that are coated with waxes, colorants, and the
15 like are included within the scope of this invention.

The total weight of the bulk composition comprised of the components described herein will necessarily vary according to the amount of bulk composition that is desired to be produced. For the purpose of calculating the weight percentage of each of the components that comprise any given amount of bulk composition, the
20 weights of all the components (i.e., the two active agents and the excipients) in a given amount of bulk composition are added together to determine the total weight of the bulk composition. As would be understood in the art, the bulk composition would not contain either solvents used in the granulation process, nor coating materials as components, and therefore such coating materials and solvents would not be included
25 in the total weight calculation of the bulk composition.

It is understood in the art that component weight ranges and specific weight amounts used herein to describe the composition of a single oral dosage unit can be scaled proportionally to make bulk composition. Of course, the component weight percentage amounts used herein are applicable to either individual oral dosage
30 units or to bulk composition.

Although the total weight of the pharmaceutical dosage unit can be varied as desired, for reasons of practicality it is preferable for the total weight of a single oral dosage unit to be in the range from 50 mg to 1000mg, and particularly from 100 mg to 800 mg.

In one embodiment of this invention, the pharmaceutical composition is comprised of the cholesterol absorption inhibitor active agent, such as ezetimibe, in an amount that is from 1% to 20% by weight of the composition, and particularly from 1.25% to 10%; the HMG-CoA reductase inhibitor active agent, such as
5 simvastatin, in an amount that is from 1% to 80% by weight of the composition, particularly from 1% to 20%, and more particularly from 5% to 10%; and at least one stabilizing agent, such as BHA, in an amount that is from 0.005% to 20% by weight, particularly from 0.01% to 2%, more particularly from 0.01% to 0.05%, and most particularly about 0.02%. In one aspect of this embodiment, the composition further
10 comprises from 0% to 0.2% (i.e., 0.2% or less), particularly from 0.001% to 0.05%, and most particularly about 0.005% by weight of propyl gallate. As an example, an oral dosage unit having a total weight in the range from 100mg to 800 mg may be comprised of from 1.25% to 10% by weight of ezetimibe, from 5 to 10% by weight of simvastatin, about 0.02% of BHA, and optionally about 0.005% by weight of propyl
15 gallate.

Within this embodiment, the pharmaceutical composition, for example but not limited to an oral dosage unit having a total weight in the range from 100mg to 800mg, is further comprised of the percent amounts by weight of the following excipients: from 1% to 80%, particularly from 5% to 20%, and most particularly
20 about 15% of microcrystalline cellulose; from 0.5% to 10%, particularly from 1% to 4%, and most particularly about 2% of HPMC; and from 0.1% to 4%, particularly from 0.5% to 2%, and most particularly about 1.5% of magnesium stearate.

Lactose is also a component of the composition and can be used in varying amounts to achieve the desired total tablet weight. For example, if for a
25 single dosage unit, the combined weight of all the components other than lactose is 36.77 mg, then 63.23 mg of lactose can be added to achieve a total dosage unit weight of 100 mg. If for a single dosage unit, the combined weight of all the components other than lactose is 73.54 mg, then 126.46 mg of lactose can be added to achieve a total dosage unit weight of 200 mg. As would be understood in the art, such
30 component weight amounts can be scaled up proportionally to make bulk composition. Generally, about 25% to 70% by weight of the composition is comprised of lactose.

In one aspect of this embodiment, croscarmellose sodium may optionally be included as a component in the composition. Accordingly, from 0% to

10% (i.e., 10% or less), particularly from 2% to 4%, and most particularly about 3% by weight of croscarmellose sodium may be included in the composition.

In another aspect of this embodiment, citric acid may optionally be included as a component in the composition. Accordingly, from 0% to 10% (i.e., 10%
5 or less), particularly from 0.1% to 1.25%, and most particularly about 0.25% by weight of citric acid may be included in the composition.

Additionally, one or more of lactic acid, malic acid, succinic acid, tartaric acid and EDTA may optionally be included in the composition.

In a second embodiment of this invention, the pharmaceutical
10 composition is comprised of from 1% to 20% by weight of the composition of a cholesterol absorption inhibitor, such as ezetimibe; from 1% to 80% by weight of the composition of at least one HMG-CoA reductase inhibitor, such as a statin; and at least one stabilizing agent in an amount that is from 0.005% to 10% by weight of the composition, and particularly from 0.01% to 5%, and more particularly from 0.01% to
15 2%.

In one aspect of this embodiment, the stabilizing agent is an antioxidant. In a further aspect, the antioxidant is selected from the group consisting of butylated hydroxyanisole, citric acid and edetate disodium and mixtures thereof..

In another aspect of this embodiment, the composition further
20 comprises one or more components selected from the group consisting of sodium lauryl sulfate, croscarmellose sodium, povidone, microcrystalline cellulose and lactose monohydrate.

In a third embodiment of this invention there is provided an oral dosage unit comprised of from 5 mg to 20 mg, and particularly 10 mg, of ezetimibe;
25 from 5 mg to 80 mg, and particularly a dosage amount selected from 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, of simvastatin; and from 0.002 mg to 0.004 mg of BHA per mg of simvastatin. More particularly, the composition also optionally comprises from 0.0005 mg to 0.001 mg of propyl gallate per mg of simvastatin. For example, the composition can be comprised of from 0.01 mg to 16 mg, and particularly from 0.02
30 mg to 0.16 mg of BHA, and additionally may be comprised of from 0.001mg to 0.05 mg, and particularly from 0.005 mg to 0.04 mg of propyl gallate. Although not required, inclusion of propyl gallate in the composition is preferred.

In one aspect of the third embodiment, the dosage unit additionally comprises from 1 mg to 640 mg, and particularly from 15 mg to 120 mg of
35 microcrystalline cellulose; from 0.5 mg to 80 mg, and particularly from 2 mg to 16

mg of HPMC; from 0.1 mg to 32 mg, and particularly from 1.5 to 12 mg of magnesium stearate; and lactose.

As discussed above, the amount of lactose in a dosage unit is a matter of choice, and can be selected to achieve the desired total tablet weight. Generally,
5 about 1000 mg or less of lactose per dosage unit, for example from about 25 mg to 1000 mg, may be used to produce a dosage unit of practicable size.

In another aspect of the third embodiment, croscarmellose sodium may optionally be included as a component in the composition. For example, an oral dosage unit may contain from 0 mg to 80 mg (i.e., 80 mg or less) of croscarmellose sodium, and particularly from 3 mg to 24 mg of croscarmellose sodium.
10

In another aspect of the third embodiment, citric acid may optionally be included as a component in the composition. For example, an oral dosage unit may contain from 0 mg to 80 mg (i.e., 80 mg or less), and particularly from 0.25 mg to 2 mg of citric acid.

15 Additionally, one or more of lactic acid, malic acid, succinic acid, tartaric acid and EDTA may optionally be included in the dosage unit.

In a fourth embodiment of this invention, there is provided a method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a pharmaceutical composition of this invention. There is also provided a method of
20 treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a pharmaceutical composition of this invention.

In an aspect of all embodiments of this invention, the amount of ezetimibe per dosage unit is 10 mg, and the amount of simvastatin per dosage unit is selected from:
25

(a) 5 mg, wherein simvastatin is from 1% to 20%, and particularly 5% by weight of the composition;

(b) 10 mg, wherein simvastatin is from 1% to 20%, and particularly
30 10% by weight of the composition;

(c) 20 mg, wherein simvastatin is from 2 % to 20%, and particularly 10% by weight of the composition;

(d) 40 mg, wherein simvastatin is from 4 % to 20%, and particularly 10% by weight of the composition; and

(e) 80 mg, wherein simvastatin is from 8% to 20%, and particularly 10% by weight of the composition.

More specifically, when the amount of simvastatin is 5% by weight of the composition, then the amount of ezetimibe is 10% by weight of the composition, and when the amount of simvastatin is 10% by weight of the composition, then the amount of ezetimibe is selected from:

- (a) 1 % to 20%, and particularly 10% by weight of the composition;
- (b) 1 % to 20%, and particularly 5% by weight of the composition;
- (c) 1 % to 20%, and particularly 2.5% by weight of the composition;
- and
- (d) 1 % to 20%, and particularly 1.25% by weight of the composition.

In another aspect of all embodiments of this invention, BHA and propyl gallate are included within the composition.

In still another aspect of all embodiments of this invention, ascorbic acid is absent from the composition. Particularly, ascorbic acid is absent from the composition, and tablet dosage units formed from the bulk composition do not have a film coating over the tablets.

In yet another aspect of all embodiments of this invention, pregelatinized starch is absent from the composition. Particularly, pregelatinized starch and ascorbic acid are both absent from the composition. More particularly, pregelatinized starch and ascorbic acid are both absent from the composition, and BHA and propyl gallate are both included within the composition.

An example within the scope of this invention includes a composition comprised of ezetimibe, simvastatin, BHA and propyl gallate, wherein absent from the composition are one or both of ascorbic acid and pregelatinized starch. A further example includes a tablet pharmaceutical dosage unit comprised of ezetimibe, simvastatin, BHA and propyl gallate, wherein ascorbic acid and a film coating over the tablet are both absent from the dosage unit, or more particularly wherein ascorbic acid, pregelatinized starch and a film coating over the tablet are all absent from the dosage unit.

A granulating fluid is used to agglomerate the bulk powders to improve the processing properties of the bulk material. For the instant composition, a mixture of ethanol and water is suitable to use as the granulating fluid. Varying proportions of water:ethanol can be used, for example in the range of 10:1 to 1:3 water to ethanol on a volumetric basis. Particularly, the granulating fluid is a 3:1

ratio, on a volumetric basis, of water to ethanol. The total quantity of granulating fluid added can be varied depending on the scale of the operation. A usual range for the granulating fluid as used with the instant composition is from about 15 to 30% by weight of the composition, and particularly about 25%. The granulating fluid is
5 removed using techniques known in the art such as tray drying, fluid bed drying, microwave drying and vacuum drying prior to compression of the bulk material into tablets.

The instant pharmaceutical composition in bulk and tablet form can be prepared by the following process. The lactose, microcrystalline cellulose,
10 simvastatin, ezetimibe, hydroxypropyl methylcellulose and croscarmellose sodium are mixed in a high shear mixer granulator to ensure uniform distribution of each component. The granulating solvent is prepared by dissolving the BHA and propyl gallate in ethanol and the citric acid is dissolved in water. The water and ethanol solutions are then mixed and sprayed onto the powder bed in the high shear mixer
15 granulator. The resultant wet mass is then dried and screened. It is then lubricated by the addition of magnesium stearate. The final lubricated powder blend is compressed into tablets.

More specific examples of oral dosage units are as follows. The oral dosage units described in Examples 1-6 can be made from appropriately scaled bulk
20 composition using the process described above.

EXAMPLE 1

Component	Amount (mg)
Simvastatin	5.0
Ezetimibe	10.0
Microcrystalline Cellulose	15.0
Lactose	63.23
HPMC	2.0
Croscarmellose Sodium	3.0
Citric Acid	0.25
Propyl Gallate	0.005
BHA	0.02
Magnesium Stearate	1.5
Total Tablet Weight	100.0

EXAMPLE 2

5

Component	Amount (mg)
Simvastatin	10.0
Ezetimibe	10.0
Microcrystalline Cellulose	15.0
Lactose	58.23
HPMC	2.0
Croscarmellose Sodium	3.0
Citric Acid	0.25
Propyl Gallate	0.005
BHA	0.02
Magnesium Stearate	1.5
Total Tablet Weight	100.0

EXAMPLE 3

Component	Amount (mg)
Simvastatin	20.0
Ezetimibe	10.0
Microcrystalline Cellulose	30.0
Lactose	126.45
HPMC	4.0
Croscarmellose Sodium	6.0
Citric Acid	0.5
Propyl Gallate	0.01
BHA	0.04
Magnesium Stearate	3.0
Total Tablet Weight	200.0

5

EXAMPLE 4

Component	Amount (mg)
Simvastatin	40.0
Ezetimibe	10.0
Microcrystalline Cellulose	60.0
Lactose	262.90
HPMC	8.0
Croscarmellose Sodium	12.0
Citric Acid	1.0
Propyl Gallate	0.02
BHA	0.08
Magnesium Stearate	6.0
Total Tablet Weight	400.0

EXAMPLE 5

Component	Amount (mg)
Simvastatin	80.0
Ezetimibe	10.0
Microcrystalline Cellulose	120.0
Lactose	535.84
HPMC	16.0
Croscarmellose Sodium	24.0
Citric Acid	2.0
Propyl Gallate	0.04
BHA	0.16
Magnesium Stearate	12.0
Total Tablet Weight	800.0

EXAMPLE 6

5

Component	Amount (mg)
Simvastatin (0.025% BHA)	10.0
Ezetimibe	10.0
Microcrystalline Cellulose	40.0
Lactose	98.98
Pregelatinized Starch	20.0
Croscarmellose Sodium	20.0
Citric Acid	0
Propyl Gallate	0
BHA	0.02
Magnesium Stearate	1.0
Total Tablet Weight	200.0

The oral dosage unit described in Example 7 can be prepared as described below.

EXAMPLE 7

Ezetimibe Granulation:	mg/tablet
Component	
Ezetimibe	10.0
Lactose	53.74
Microcrystalline Cellulose	20.0
Croscarmellose Sodium	8.0
Povidone	4.0
BHA	0.01
Ascorbic Acid	2.5
Citric Acid	1.25
Simvastatin Granulation:	
Component	
Simvastatin (0.025% BHA)	10.0
Lactose	21.87
Microcrystalline Cellulose	10.0
Croscarmellose Sodium	4.0
Povidone	2.0
BHA	0.005
Ascorbic Acid	1.25
Citric Acid	0.625
Lubricant	
Magnesium Stearate	0.75
Total Weight	150.0

- 5 Ezetimibe Granulation: BHA and citric acid in the amounts described above for the ezetimibe granulation were dissolved in a 70:30 water/alcohol mixture. Povidone (PVP) and ascorbic acid in the amounts described above for the ezetimibe granulation were dissolved in water. The ezetimibe, lactose, half of the croscarmellose sodium and half of the microcrystalline cellulose in the amounts

described above for the ezetimibe granulation were mixed in a Hobart mixer. While blending, the BHA solution described above was added to the ezetimibe mixture. The resulting mixture was granulated using the povidone/ascorbic acid solution described above. The resulting wet mass was granulated as described above and then blended
5 with the other half of the croscarmellose sodium and microcrystalline cellulose.

Simvastatin Granulation: BHA and citric acid in the amounts described above for the simvastatin granulation were dissolved in a 7:3 water/alcohol mixture. Povidone (PVP) and ascorbic acid in the amounts described above for the simvastatin granulation were dissolved in water. The simvastatin, lactose, half of the
10 croscarmellose sodium and half of the microcrystalline cellulose in the amounts described above for the simvastatin granulation were mixed in a Hobart mixer. While blending, the BHA solution described above was added to the simvastatin mixture. The resulting mixture was granulated using the povidone/ascorbic acid solution described above. The resulting wet mass was granulated as described above and then
15 blended with the other half of the croscarmellose sodium and microcrystalline cellulose.

Composite Granules: The ezetimibe granules and simvastatin granules were mixed together in a Turbula mixer. Magnesium stearate was mixed with the granule mixture and compressed into tablets in a manner similar to that described
20 above.

Accordingly, in another embodiment, the present invention provides a therapeutic combination comprising (a) a first amount of from 1% to 20% by weight of at least one sterol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof and from 0.005% to 10% by weight of at least one first stabilizing
25 agent; and (b) a second amount of from 1% to 80% by weight of at least one HMG CoA reductase inhibitor and from 0.005% to 10% by weight of at least one second stabilizing agent, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of atherosclerosis.
30 The first stabilizing agent and the second stabilizing agent can be the same or chemically different and include for example the stabilizing agents listed above.

As used herein, "therapeutic combination" means the administration of two or more therapeutic agents, such as sterol absorption inhibitor(s) and HMG CoA reductase inhibitor(s), to prevent or treat atherosclerosis or any of its associated
35 conditions, such as are discussed above. Such administration includes

coadministration of these therapeutic agents in a substantially simultaneous manner, such as in a single tablet or capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each therapeutic agent. Also, such administration includes use of each type of therapeutic agent in a sequential manner. In either case, 5 the treatment using the combination therapy will provide beneficial effects in treating the atherosclerotic condition. A potential advantage of the combination therapy disclosed herein may be a reduction in the required amount of an individual therapeutic compound or the overall total amount of therapeutic compounds that are effective in treating the atherosclerotic condition. By using a combination of 10 therapeutic agents, the side effects of the individual compounds can be reduced as compared to a monotherapy, which can improve patient compliance. Also, therapeutic agents can be selected to provide a broader range of complimentary effects or complimentary modes of action.

15 While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a 20 consequence of variations in the responsiveness of the mammal being treated for any of the indications for the active agents used in the instant invention as indicated above. It is intended, therefore, that the invention be defined by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprised of from 1% to 20% by weight of ezetimibe; from 1% to 80% by weight of simvastatin; and from 0.01% to 2% by weight of BHA.
2. The composition of claim 1 comprised of from 1.25% to 10% of ezetimibe, and from 1% to 20% of simvastatin.
3. The composition of claim 2 comprised of from 5% to 10% of simvastatin.
4. The composition of claim 1 comprised of 0.01% to 0.05% of BHA.
5. The composition of claim 4 comprised of about 0.02% of BHA.
6. The composition of claim 1 further comprised of 0.2% or less by weight of propyl gallate.
7. The composition of claim 6 comprised of from 0.001% to 0.05% by weight of propyl gallate.
8. The composition of claim 7 comprised of about 0.005% by weight of propyl gallate.
9. The composition of claim 1 further comprised of from 5% to 20% by weight of microcrystalline cellulose; from 1% to 4% by weight of hydroxypropyl methylcellulose; and from 0.5% to 2% by weight of magnesium stearate.
10. The composition of claim 1 further comprised of 10% or less by weight of croscarmellose sodium.

11. The composition of claim 10 comprised of from 2% to 4% by weight of croscarmellose sodium.
12. The composition of claim 1 further comprised of 10% or less
5 by weight of citric acid.
13. The composition of claim 12 comprised of from 0.1% to 1.25% by weight of citric acid.
14. A pharmaceutical dosage unit comprised of from 5 mg to 20 mg of ezetimibe; from 5 mg to 80 mg of simvastatin; and from 0.002 mg to 0.004 mg of BHA per mg of simvastatin.
15. The dosage unit of claim 14 comprised of 10 mg of ezetimibe and a dosage amount of simvastatin selected from 5 mg, 10mg, 20 mg, 40 mg and 80 mg.
16. The dosage unit of claim 14 further comprised of 0.0005 mg to 0.001 mg of propyl gallate per mg of simvastatin.
17. The dosage unit of claim 14 additionally comprised of from 1 mg to 640 mg of microcrystalline cellulose; from 0.5 mg to 80 mg of hydroxypropyl methylcellulose; from 0.1 mg to 32 mg of magnesium stearate; and lactose.
18. The dosage unit of claim 17 comprised of from 15 mg to 120 mg of microcrystalline cellulose; from 2 mg to 16 mg of hydroxypropyl methylcellulose; and from 1.5 to 12 mg of magnesium stearate.
19. The dosage unit of claim 14 further comprised of 80 mg or less
30 of croscarmellose sodium.
20. The dosage unit of claim 14 further comprised of 80 mg or less of citric acid.

21. The composition of claim 1 provided that it is not comprised of ascorbic acid.

22. The composition of claim 21 wherein the composition is a tablet and provided that the tablet does not have a film coating.

23. The composition of claim 1 provided that it is not comprised of pregelatinized starch.

24. A pharmaceutical composition comprising:
(a) from 1% to 20% by weight of a cholesterol absorption inhibitor;
(b) from 1% to 80% by weight of at least one HMG-CoA reductase inhibitor; and
(c) from 0.005% to 10% by weight of at least one stabilizing agent.

25. The composition of claim 24, wherein the cholesterol absorption inhibitor is ezetimibe.

26. The composition of claim 24, wherein the HMG-CoA reductase inhibitor is a statin.

27. The composition of claim 26, wherein the statin is selected from the group consisting of lovastatin, simvastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, cerivastatin, and pitavastatin.

28. The composition of claim 27, wherein the statin is simvastatin.

29. The composition of claim 27, wherein the statin is lovastatin.

30. The composition of claim 27, wherein the statin is atorvastatin.

31. The composition of claim 24, wherein the stabilizing agent is an antioxidant.

32. The composition of claim 31, wherein the antioxidant is selected from the group consisting of butylated hydroxyanisole, ascorbic acid, citric acid and edetate disodium.

5 33. The composition of claim 24 provided that it is not comprised of ascorbic acid.

34. The composition of claim 24 provided that it is not comprised of pregelatinized starch.

10

35. The composition of claim 24, wherein the stabilizing agent comprises 0.01% to 5% by weight of the composition.

15 36. The composition of claim 35, wherein the stabilizing agent comprises 0.01% to 2% by weight of the composition.

37. The composition of claim 24, further comprising one or more compounds selected from the group consisting of sodium lauryl sulfate, croscarmellose sodium, pregelatinized starch, povidone, microcrystalline cellulose and lactose monohydrate.

20

38. A method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a composition of claim 1.

25

39. A method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a composition of claim 24.

30 40. A therapeutic combination comprising (a) a first amount of from 1% to 20% by weight of at least one sterol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof and from 0.005% to 10% by weight of at least one first stabilizing agent; and (b) a second amount of from 1% to 80% by weight of at least one HMG CoA reductase inhibitor and from 0.005% to 35 10% by weight of at least one second stabilizing agent, wherein the first amount and

the second amount together comprise a therapeutically effective amount for the treatment or prevention of atherosclerosis.

INTERNATIONAL SEARCH REPORT

Int I Application No
PCT/US 03/22889

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/397 A61K31/35 A61K31/22 A61K31/365 A61K31/40
A61K47/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GAGNE C ET AL: "EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH ATORVASTATIN OR SIMVASTATIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA" CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 105, no. 21, 28 May 2002 (2002-05-28), pages 2469-2475, XP001132086 ISSN: 0009-7322 See abstract	1-40
Y	WO 95 08532 A (CLADER JOHN W ;DUGAR SUNDEEP (US); SCHERING CORP (US); BURNETT DUA) 30 March 1995 (1995-03-30) page 1, line 4-8 page 23, line 20-35; claims 7,15-17; example 6	1-40

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 October 2003

Date of mailing of the international search report

10/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allnutt, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/22889

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DAVIDSON MICHAEL ET AL: "Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia"</p> <p>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 39, no. 5 Supplement A, 6 March 2002 (2002-03-06), pages 226A-227A, XP009019354</p> <p>51st Annual Scientific Session of the American College of Cardiology; Atlanta, GA, USA; March 17-20, 2002 ISSN: 0735-1097</p> <p>See under "methods" heading</p> <p style="text-align: center;">----</p>	1-40
Y	<p>US 6 218 403 B1 (HERBERT JEAN MARC ET AL) 17 April 2001 (2001-04-17) examples 1,2</p> <p style="text-align: center;">----</p>	1-40
Y	<p>US 5 366 738 A (RORK GERALD S ET AL) 22 November 1994 (1994-11-22) example 7</p> <p style="text-align: center;">----</p>	1-40
Y	<p>ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients-3rd Edition", PHARMACEUTICAL PRESS XP002258396 page 49 page 47</p> <p style="text-align: center;">----</p>	1-40
P,A	<p>DAVIDSON MICHAEL H ET AL: "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia."</p> <p>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 40, no. 12, 18 December 2002 (2002-12-18), pages 2125-2134, XP001155704 ISSN: 0735-1097 (ISSN print) See abstract, 1.6-13 page 2132, column 2, line 25-30</p> <p style="text-align: center;">-----</p>	1-40

INTERNATIONAL SEARCH REPORT

Intel Application No

PC1/US 03/22889

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9508532	A	30-03-1995	US 5631365 A	20-05-1997
			AT 180249 T	15-06-1999
			AU 681445 B2	28-08-1997
			AU 7795294 A	10-04-1995
			CN 1131416 A ,B	18-09-1996
			CZ 9600839 A3	14-08-1996
			DE 69418613 D1	24-06-1999
			DE 69418613 T2	30-09-1999
			DK 720599 T3	08-11-1999
			EP 0720599 A1	10-07-1996
			ES 2132432 T3	16-08-1999
			FI 961300 A	21-03-1996
			GR 3030312 T3	30-09-1999
			HU 73852 A2	30-09-1996
			IL 110956 A	11-01-2001
			JP 2803908 B2	24-09-1998
			JP 8509989 T	22-10-1996
			KR 186853 B1	01-05-1999
			NO 961133 A	20-03-1996
			NZ 274041 A	19-12-1997
			PL 313589 A1	08-07-1996
			RU 2138480 C1	27-09-1999
			SG 46208 A1	20-02-1998
			SK 35596 A3	05-02-1997
			TW 427974 B	01-04-2001
			WO 9508532 A1	30-03-1995
			US RE37721 E1	28-05-2002
			US 5767115 A	16-06-1998
			US 5846966 A	08-12-1998
			ZA 9407086 A	14-03-1995
			CZ 288891 B6	12-09-2001
US 6218403	B1	17-04-2001	FR 2751540 A1	30-01-1998
			AU 725949 B2	26-10-2000
			AU 3852697 A	20-02-1998
			BR 9710560 A	17-08-1999
			CA 2261099 A1	05-02-1998
			CN 1228698 A ,B	15-09-1999
			CZ 9900176 A3	12-05-1999
			EE 9900028 A	16-08-1999
			EP 0914124 A1	12-05-1999
			WO 9804259 A1	05-02-1998
			HU 9903752 A2	28-03-2000
			JP 2000500781 T	25-01-2000
			KR 2000029484 A	25-05-2000
			NO 990321 A	22-03-1999
			NZ 333826 A	29-09-2000
			PL 331339 A1	05-07-1999
			RU 2176504 C2	10-12-2001
			SK 7899 A3	12-07-1999
			TR 9900154 T2	21-04-1999
			ZA 9706247 A	15-01-1999
US 5366738	A	22-11-1994	US 5543154 A	06-08-1996
			US 5882682 A	16-03-1999
			AT 157001 T	15-09-1997
			AU 660057 B2	08-06-1995
			AU 3034892 A	12-08-1993

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/22889

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5366738	A	BG 61751 B1	29-05-1998
		BG 98805 A	31-03-1995
		BR 1100345 A3	18-07-2000
		CA 2085871 A1	28-06-1993
		CN 1074368 A	21-07-1993
		CZ 9401570 A3	15-12-1994
		DE 69221711 D1	25-09-1997
		DE 69221711 T2	12-03-1998
		DK 549331 T3	15-09-1997
		EP 0549331 A1	30-06-1993
		ES 2106838 T3	16-11-1997
		FI 943011 A	22-06-1994
		GR 3024885 T3	30-01-1998
		HU 70437 A2	30-10-1995
		IL 104189 A	31-10-1996
		JP 2111859 C	21-11-1996
		JP 5255071 A	05-10-1993
		JP 8009534 B	31-01-1996
		LV 12082 A	20-07-1998
		LV 12082 B	20-09-1998
		MX 9207541 A1	30-06-1994
		NO 942430 A	27-06-1994
		NZ 245514 A	22-12-1994
		PL 171110 B1	28-03-1997
		RO 112810 B1	30-01-1998
		RU 2127586 C1	20-03-1999
		SK 76994 A3	10-05-1995
		WO 9312765 A1	08-07-1993
		ZA 9209993 A	30-06-1993

Continuation of Box I.1

Although claims 38 and 39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 38,39

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 24,38,39,40

1. In claim 24, the expression "cholesterol absorption inhibitor" is defined by reference to a desirable characteristic or property. This leads to a lack of clarity (Article 6 PCT) and is such as to render a meaningful search over the whole claimed scope impossible since it is not possible to identify which specific compounds are encompassed by this term.

In addition, this term encompasses a very large number of possible compounds which may have this characteristic and a complete search is therefore not possible. Consequently, the search has been carried out based on ezetimibe and azetidinones as the cholesterol absorption inhibitor since these are the only examples provided by the application.

2. The same reasoning applies for the expression "sterol absorption inhibitor" in claim 40.

3. Present claims 38 and 39 relate to an extremely large number of possible diseases due to the expression "vascular condition". Consequently the search has been restricted to the term as such and related diseases provided in the description, namely coronary heart disease, hyperlipidemia, hypercholesterolemia, atherosclerotic disease and myocardial infarction (pg 3, l. 19-21).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/US 03/22889

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 38, 39
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 24, 38, 39, 40
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.